

SEQUENCE LISTING

<110> BUSCHLE, MICHAEL
HABEL, ANDRE
FRITZ, JORG
PRINZ, KARIN
LINGNAU, KAREN

<120> IMPROVED VACCINES

<130> SONN:076US

<140> UNKNOWN

<141> 2005-09-23

<150> PCT/EP2004/003002

<151> 2004-03-22

<150> EP 03450072.8

<151> 2003-03-24

<150> EP 03450084.3

<151> 2003-04-11

<150> EP 03450171.89

<151> 2003-07-11

<160> 20

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<220>

<221> MOD_RES

<222> (1)..(9)

<223> X = any positively charged amino acid

<400> 1

Xaa Glx Xaa Glx Glx Glx Xaa Glx Xaa

1

5

<210> 2

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<220>

<221> MOD_RES

<222> (1)..(10)
 <223> X = any positively charged amino acid

 <400> 2
 Xaa Glx Xaa Glx Glx Glx Glx Xaa Glx Xaa
 1 5 10

 <210> 3
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

 <220>
 <221> MOD_RES
 <222> (1)..(11)

 <400> 3
 Xaa Glx Xaa Glx Glx Glx Glx Glx Xaa Glx Xaa
 1 5 10

 <210> 4
 <211> 12
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

 <220>
 <221> MOD_RES
 <222> (1)..(12)
 <223> X = any positively charged amino acid

 <400> 4
 Xaa Glx Xaa Glx Glx Glx Glx Glx Glx Xaa Glx Xaa
 1 5 10

 <210> 5
 <211> 13
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 Peptide

 <220>
 <221> MOD_RES
 <222> (1)..(13)
 <223> X = any positively charged amino acid

 <400> 5
 Xaa Glx Xaa Glx Glx Glx Glx Glx Glx Xaa Glx Xaa

1 5 10

<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 6
Lys Leu Lys Leu Leu Leu Leu Lys Leu Lys
1 5 10

<210> 7
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 7
Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys
1 5 10 15

Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys
20 25

<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 8
Gly Leu Cys Thr Leu Val Ala Met Leu
1 5

<210> 9
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 9
Ile Ala Ser Asn Glu Asn Met Glu Thr Met
1 5 10

<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 10
Thr Met Leu Tyr Asn Lys Met Glu Phe
1 5

<210> 11
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 11
Ser Ser Ile Ala Ala Gln Asp Ala Leu
1 5

<210> 12
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 12
Val Thr Ile Leu Asn Leu Ala Leu Leu
1 5

<210> 13
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 13
Lys Phe Pro Gly Gly Gly Gln Ile Val Gly Gly Val Tyr Leu Leu Pro
1 5 10 15

Arg Arg Gly Pro Arg Leu
20

<210> 14

<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 14
Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr
1 5 10

<210> 15
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 15
Asp Leu Met Gly Tyr Ile Pro Ala Val
1 5

<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 16
Cys Ile Asn Gly Val Cys Trp Thr Val
1 5

<210> 17
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 17
His Met Trp Asn Phe Ile Ser Gly Ile Gln Tyr Leu Ala Gly Leu Ser
1 5 10 15

Thr Leu Pro Gly Asn Pro Ala
20

<210> 18
<211> 9
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 18

Tyr Met Asp Gly Thr Met Ser Gln Val
1 5

<210> 19

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Primer

<400> 19

tccatgactt tcctgatgct

SEQUENCE LISTING

<110> BUSCHLE, MICHAEL
LINGNAU, KAREN

<120> USE OF ALUM AND A TH1 IMMUNE RESPONSE INDUCING ADJUVANT
FOR ENHANCING IMMUNE RESPONSES

<130> SONN:077US

<140> UNKNOWN

<141> 2005-09-23

<150> PCT/EP2004/003029

<151> 2004-03-22

<150> EP 03450072.8

<151> 2003-03-24

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<220>

<221> MOD_RES

<222> (1)..(9)

<223> X = any positively charged amino acid

<400> 1

Xaa Glx Xaa Glx Glx Glx Xaa Glx Xaa

1

5

<210> 2

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<220>

<221> MOD_RES

<222> (1)..(10)

<223> X = any positively charged amino acid

<400> 2

Xaa Glx Xaa Glx Glx Glx Glx Xaa Glx Xaa

1

5

10

<210> 3

<211> 11

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<220>
<221> MOD_RES
<222> (1)..(11)

<400> 3
Xaa Glx Xaa Glx Glx Glx Glx Xaa Glx Xaa
1 5 10

<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<220>
<221> MOD_RES
<222> (1)..(12)
<223> X = any positively charged amino acid

<400> 4
Xaa Glx Xaa Glx Glx Glx Glx Glx Xaa Glx Xaa
1 5 10

<210> 5
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<220>
<221> MOD_RES
<222> (1)..(13)
<223> X = any positively charged amino acid

<400> 5
Xaa Glx Xaa Glx Glx Glx Glx Glx Glx Xaa Glx Xaa
1 5 10

<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 6

Lys Leu Lys Leu Leu Leu Leu Lys Leu Lys
1 5 10

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Primer

<400> 7

tcctgatgct

20

<210> 8

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 8

Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys
1 5 10 15

Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys
20 25

SEQUENCE LISTING

<110> BUSCHLE, MICHAEL
HABEL, ANDRE
FRITZ, JORG
PRINZ, KARIN
LINGNAU, KAREN

<120> IMPROVED VACCINES

<130> SONN:076US

<140> UNKNOWN

<141> 2005-09-23

<150> PCT/EP2004/003002

<151> 2004-03-22

<150> EP 03450072.8

<151> 2003-03-24

<150> EP 03450084.3

<151> 2003-04-11

<150> EP 03450171.89

<151> 2003-07-11

<160> 18

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<220>

<221> MOD_RES

<222> (1)..(9)

<223> X = any positively charged amino acid

<400> 1

Xaa Glx Xaa Glx Glx Glx Xaa Glx Xaa

1

5

<210> 2

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<220>

<221> MOD_RES

<223> X = any positively charged amino acid

<400> 2

Xaa Glx Xaa Glx Glx Glx Glx Xaa Glx Xaa
1 5 10

<210> 3

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<220>

```
<221> MOD_RES
```

$$\langle 222 \rangle \quad (1) \quad \overline{1} \quad (11)$$

<400> 3

Xaa Glx Xaa Glx Glx Glx Glx Glx Xaa Glx Xaa
1 5 10

<210> 4

<211> 12

<212> PRT

<213> Artificial Sequence

$\langle 220 \rangle$

<223> Description of Artificial Sequence: Synthetic Peptide

<220>

```
<221> MOD_RES
```

$$\langle 222 \rangle \quad (1) \quad \bar{\cdot} \cdot (12)$$

<223> X = any positively charged amino acid

<400> 4

Xaa Glx Xaa Glx Glx Glx Glx Glx Glx Xaa Glx Xaa
1 5 10

<210> 5

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<220>

<221> MOD RES

$\langle 222 \rangle$ (1) $\bar{1}$ (13)

<223> X = any positively charged amino acid

<400> 5

Xaa Glx Xaa Glx Glx Glx Glx Glx Glx Glx Xaa Glx Xaa

| | | |
|---|---|----|
| 1 | 5 | 10 |
|---|---|----|

<210> 6
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 6
 Lys Leu Lys Leu Leu Leu Leu Lys Leu Lys
 1 5 10

<210> 7
 <211> 26
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 7
 Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys
 1 5 10 15
 Ile Cys Ile Cys Ile Cys Ile Cys Ile Cys
 20 25

<210> 8
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 8
 Gly Leu Cys Thr Leu Val Ala Met Leu
 1 5

<210> 9
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic Peptide

<400> 9
 Ile Ala Ser Asn Glu Asn Met Glu Thr Met
 1 5 10

<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 10
Thr Met Leu Tyr Asn Lys Met Glu Phe
1 5

<210> 11
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 11
Ser Ser Ile Ala Ala Gln Asp Ala Leu
1 5

<210> 12
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 12
Val Thr Ile Leu Asn Leu Ala Leu Leu
1 5

<210> 13
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Peptide

<400> 13
Lys Phe Pro Gly Gly Gly Gln Ile Val Gly Gly Val Tyr Leu Leu Pro
1 5 10 15

Arg Arg Gly Pro Arg Leu
20

<210> 14

<211> 14
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 14

Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr
1 5 10

<210> 15
<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 15

Asp Leu Met Gly Tyr Ile Pro Ala Val
1 5

<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 16

Cys Ile Asn Gly Val Cys Trp Thr Val
1 5

<210> 17
<211> 23
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 17

His Met Trp Asn Phe Ile Ser Gly Ile Gln Tyr Leu Ala Gly Leu Ser
1 5 10 15

Thr Leu Pro Gly Asn Pro Ala
20

<210> 18
<211> 9
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 18

Tyr Met Asp Gly Thr Met Ser Gln Val

1

5

<210> 19

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Primer

<400> 19

tccatgacit tcctgatgct

<210> 20

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Primer

<400> 18

tccatgacgt tcctgatg